A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

ClinicalTrials.gov ID: NCT03194542

Public ClinicalTrials.gov record NCT03194542. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 16, 2026, 2:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence

Study identification

NCT ID: NCT03194542
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Celgene; Industry
Enrollment: 95 participants

Conditions and interventions

Conditions

Interventions

Luspatercept Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 14, 2017
Primary completion: Jul 17, 2022
Completion: Jul 17, 2022
Last update posted: Aug 23, 2023

2017 – 2022

United States locations

U.S. sites: 20
U.S. states: 7
U.S. cities: 10

Facility	City	State	ZIP	Site status
Local Institution - 102	Phoenix	Arizona	85054	—
Mayo Clinic - Arizona	Phoenix	Arizona	85054	—
Local Institution - 103	Stanford	California	94305	—
Stanford Cancer Center	Stanford	California	94305	—
Local Institution - 101	Jacksonville	Florida	32224	—
Mayo Clinic - Jacksonville	Jacksonville	Florida	32224	—
Local Institution - 107	Orange City	Florida	32763	—
Mid Florida Hematology and Oncology Centers, PA	Orange City	Florida	32763	—
H. Lee Moffitt Cancer Center and Research Institute	Tampa	Florida	33612	—
Local Institution - 108	Tampa	Florida	33612	—
Local Institution - 104	New York	New York	10029	—
Mount Sinai Medical Center	New York	New York	10029	—
Cleveland Clinic	Cleveland	Ohio	44195	—
Local Institution - 109	Cleveland	Ohio	44195	—
Avera Research Institute	Sioux Falls	South Dakota	57105	—
Local Institution - 105	Sioux Falls	South Dakota	57105	—
Local Institution - 100	Houston	Texas	77030	—
MD Anderson Cancer Center The University of Texas	Houston	Texas	77030	—
Local Institution - 106	San Antonio	Texas	78229	—
University of Texas Health Science Center at San Antonio	San Antonio	Texas	78229	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03194542, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 23, 2023 · Synced May 16, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03194542 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →